Mylan Inc.
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1961-01-01
- Employees
- 35K
- Market Cap
- -
- Website
- https://www.mylan.com/
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 876
- Registration Number
- NCT03129321
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 654
- Registration Number
- NCT03107611
- Locations
- 🇺🇸
Research Facility 28, Overland Park, Kansas, United States
🇺🇸Research Facility 1, Miami Lakes, Florida, United States
🇺🇸Research Facility 6, Boynton Beach, Florida, United States
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT03095456
- Locations
- 🇺🇸
Clinical Research of Rock Hill, Rock Hill, South Carolina, United States
Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03064113
- Locations
- 🇳🇿
P3 Research, Wellington, New Zealand
A Survey on Efficacy and Safety in Patients With Endometriosis
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02921763
- Locations
- 🇯🇵
Mylan Investigational Site A, Kamigyo-ku, Kyoto, Japan
🇯🇵Mylan Investigational Site D, Saitama, Iwatsukiku, Japan
🇯🇵Mylan Investigational Site E, Kyoto, Ukyouku, Japan
Thorough QT (TQT) Study of TD-4208 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02820311
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02772159
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
MYL-1401A Efficacy and Safety Comparability Study to Humira®
- Conditions
- Interventions
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 294
- Registration Number
- NCT02714322
- Locations
- 🇷🇺
Mylan investigational site 156, Kazan, Russian Federation
🇺🇦Mylan Investigational site 159, Kharkiv, Ukraine
🇺🇦Mylan investigational site 161, Uzhhorod, Ukraine
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT02666430
- Locations
- 🇨🇦
Mylan Investigator Site., Vancouver, British Columbia, Canada
🇸🇰Mylan Investigator Site, Zilina, Slovakia
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02581592
- Locations
- 🇺🇸
Orlando Clinical Research Center (OCRD), Orlando, Florida, United States